Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non-Current Deferred Tax Liability for 9 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $30.0 million for FY2025, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $30.0 million at Ultragenyx Pharmaceutical, roughly flat from $30.1 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $33.3 million in Q1 2021, with the low at $30.0 million in Q4 2024.
  • Average Non-Current Deferred Tax Liability over 5 years is $31.5 million, with a median of $31.7 million recorded in 2022.
  • The sharpest move saw Non-Current Deferred Tax Liability changed 0.0% in 2021, then decreased 5.08% in 2023.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $33.3 million in 2021, then decreased by 4.92% to $31.7 million in 2022, then fell by 5.08% to $30.1 million in 2023, then decreased by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $30.0 million, $30.1 million, and $30.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.